The slight EPS miss is negligible given the company's clinical-stage profile. Focus on upcoming binary catalysts: pivotal opakalim epilepsy data and taldefgrobep obesity topline results in 2H 2026. Cash runway of $352M provides visibility into 2027. Monitor initiation of degrader pivotal trials by mid-year.
Price Chart
Executive Summary
Biohaven reported Q1 2026 GAAP net loss of $130.5M ($0.88/share), marginally missing the Street consensus of $0.86/share by ~2.3%. However, operating expenses decreased significantly YoY due to strategic reprioritization, and cash position improved to $351.8M. Pipeline progress remains the key focus, with completed enrollment in the Phase 2 obesity study and pivotal data expected across multiple programs in 2H 2026.
Key Financial Metrics
Key Facts
- GAAP net loss of $130.5M ($0.88/share) vs $221.7M ($2.17/share) in Q1 2025; consensus was $0.86/share (miss by 2.3%)
- Non-GAAP adjusted net loss of $102.2M ($0.69/share) vs $166.8M ($1.64/share) YoY
- Cash, cash equivalents, marketable securities and restricted cash: $351.8M as of March 31, 2026, up from $322M at Dec 31, 2025
- Completed enrollment in Phase 2 obesity study for taldefgrobep alfa; topline data expected 2H 2026
- Pivotal trial initiations for BHV-1400 (IgAN) and BHV-1300 (Graves' disease) expected mid-2026
- Pivotal data for opakalim in focal epilepsy expected 2H 2026
- R&D expenses decreased 45% YoY to $103.8M due to strategic reprioritization and lower share-based compensation
Financial Impact
Net loss narrowed 41% YoY but missed consensus by $0.02/share. Cash burn improved with R&D expenses down 45%.
Risk Factors
- Clinical trial failure risk for opakalim, taldefgrobep, and degrader programs
- Potential need for additional capital raises causing dilution
- No approved products or revenue; reliant on pipeline success
Market Snapshot
Investment Themes
Documents Analyzed
This report is based on 6 SEC documents filed with EDGAR.
| Document | Accession Number |
|---|---|
| 8-K Filing (Primary) | 0001935979-26-000044 |
| Document: bhvn-20260504.htm | 0001935979-26-000044 |
| Document: 0001935979-26-000044-index-headers.html | 0001935979-26-000044 |
| Document: 0001935979-26-000044-index.html | 0001935979-26-000044 |
| Document: 0001935979-26-000044.txt | 0001935979-26-000044 |
| 8-K Data (Synthetic) | 0001935979-26-000044 |
Filters
| Type | Now | ||||
|---|---|---|---|---|---|
Oct 22, 2026 4d ago | 8-K | $14.69 | awaiting T+5 | — | $13.88 (−5.51%) |
Oct 15, 2026 10d ago | 8-K | $10.78 $13.88 | ▲ +28.76% | ▲ +29.19% | $13.88 (+28.76%) |
Sep 9, 2026 6w ago | 8-K | $12.79 $13.89 | ▼ −8.60% | ▼ −9.10% | $13.88 (−8.52%) |
Aug 26, 2026 8w ago | 8-K | $16.95 $15.69 | ▼ −7.43% | ▼ −7.31% | $13.88 (−18.11%) |
Aug 10, 2026 10w ago | 8-K | $14.49 $13.57 | ▼ −6.35% | ▼ −5.95% | $13.88 (−4.21%) |
Jul 9, 2026 15w ago | 8-K | $15.55 $14.17 | ▼ −8.87% | ▼ −8.31% | $13.88 (−10.74%) |
May 27, 2026 21w ago | 8-K | $10.24 $11.40 | ▲ +11.33% | ▲ +11.01% | $13.88 (+35.55%) |
May 4, 2026 24w ago | 424B5 | $9.71 $9.20 | ▲ +5.25% | ▲ +7.24% | $13.88 (−42.95%) |
May 4, 2026 24w ago | S-3ASR | $9.71 $9.20 | ▼ −5.25% | ▼ −7.24% | $13.88 (+42.95%) |
May 4, 2026 24w ago | 8-K | $9.71 $9.20 | ▼ −5.25% | ▼ −7.24% | $13.88 (+42.95%) |
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers